2026-10-25
Does not pass
Humacyte, does not pass the ethical screen. The binding factor is interest/revenue 126.9%.
NAS100 26,990 +1.35%
S&P 7,377 +0.31%
GOLD $4,075 −0.94%
BTC $75,677 −0.09%
VIX 25.64 −9.01%
latest tape · as of 20:08 UTC
The Screen · Healthcare · Biotechnology
Humacyte, Inc.
HUMA · Nasdaq · USD · Market cap $98M · 184 employees
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of ana…
FAIL · Does not pass the screen0.45 USD
Price as of 6 Nov 2026Daily close, not a live quote
Screened 2026-11-06 · the tape above runs as of 20:08 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price0.45 USD at the 6 Nov 2026 close
- Fair valueUnder review: our model's value is 2.83x the price, above our 1.99x limit.
- Our regime readMarkup, as of 7 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans heavily to calls (put/call 0.00)
- Last reviewed6 Nov 2026 (1 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
PRICE · ONE YEAR
Our fair-value range: range not available (screen dated 2026-11-06).
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.00, read 2026-11-03
- Ethical does not pass the values gate
Price0.45 USD
Fair valueUnder review
Ethical score82.5/100
Our investment reviews on this name
2026-10-18Read Distribution0.44+1.9% to today Markdown gives way to Distribution after a 23% slide in 2 weeks
2026-10-02Read Markdown0.57-21.2% to today ✓Markup gives way to Markdown after a 23% slide in 4 weeks
2026-09-01Read Markup0.73-39.0% to today Distribution gives way to Markup after an 11% rise in 4 weeks
2026-08-01Read Distribution0.66-32.6% to today ✓Markup gives way to Distribution after a 51% slide in 4 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its markup label.
Humacyte, Inc. holds its Markup at $0.45. The statistical read favours the buyers, held for 12 days.
| Phase | Markup |
| Quantitative state | The statistical read favours the buyers, held for 12 days |
| Price at the screen | $0.45 |
| Valuation | N/A trailing · -1.43 forward price to earnings |
| Values screen | FAIL · score 82.5 |
| Beta | 2.44 |
Five Screens, Shown in Full
Does not pass. Interest/revenue 126.9%
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 26.05% | Below 33% | Interest-bearing debt is just 26.0% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 20.13% | Below 33% | Cash held in interest-bearing accounts and securities is 20.1% of assets, under the one-third limit. | Pass |
| Receivables | 0.00% | Below 49% | Money owed to the company is 0.0% of assets, under the 49% limit. | Pass |
| Revenue purity | 126.94% | Below 5% | 126.9% of revenue comes from non-compliant sources, over the 5% line. | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Humacyte, does not pass the ethical screen. The binding factor is interest/revenue 126.9%.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
Clears
Humacyte, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 26%, inside the ~33% line, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
Follow this verdict
Get an email when HUMA's ethical verdict changes
Today HUMA does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Fair value under review. Our model's value is 2.83x the price, above our 1.99x limit. We show no fair value, margin of safety or value read built on it until the review clears.
How a fair value is estimated: discounted cash flow (DCF).
The Street's RangeThird-party analyst targets: 6 covering, consensus Buy. The average target sits +151% from the screen price.
Where our models see it going: no fair-value estimate yet, range not available, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words| Forward P/E | -1.4x |
| EPS, trailing | -0.51 |
| EPS, forward | -0.25 |
| Revenue growth | +34.9%strong top-line growth |
| Profit margin | 0.0%currently unprofitable |
| Return on equity | -547.9%not currently earning a positive return on equity |
| FCF yield | -59.36% |
| Debt to equity | 2.14heavy leverage: higher risk if revenue softens |
| Current ratio | 6.21comfortably covers its short-term bills |
| Beta | 2.44much more volatile than the market |
| Short interest, float | 0.11% |
| 52-week range | 0.34 - 1.90 |
| Market cap | $98M |
| Employees | 184 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeHUMA trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-11-01
Distribution $0.41
-6.5% Entry 9
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 6.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 51%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (7 analysts) rates it buy, with a mean price target of $5.
2026-10-25
Distribution $0.44
+0.0% Entry 8
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 51%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (7 analysts) rates it buy, with a mean price target of $5.
2026-10-18
Distribution · changed $0.44
-22.7% Entry 7
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 22.7% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 51%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (7 analysts) rates it buy, with a mean price target of $5.
2026-10-02
Markdown · changed $0.57
-22.6% Entry 6
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 22.6% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 51%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (7 analysts) rates it buy, with a mean price target of $5.
2026-09-01
Markup · changed $0.73
+10.6% Entry 5
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 10.6% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 51%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (7 analysts) rates it buy, with a mean price target of $5.
2026-08-01
Distribution · changed $0.66
-50.8% Entry 4
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 50.8% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 51%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (7 analysts) rates it buy, with a mean price target of $5.
2026-07-18
Markup $1.35
+0.0% Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 51%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (7 analysts) rates it buy, with a mean price target of $5.
2026-07-03
Markup $1.35
+0.0% Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02
Markup $1.35
Entry 1
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Humacyte Announces Phase 3 V012 Trial Results for ATEV in Women Requiring Hemodialysis Access Accepted for a Late-Breaking Session Presentation at ASN Kidney Week 2026 Yahoo Finance · 26d ago
- Humacyte (HUMA) Stock Fair Value Moves Lower After Analyst Target Cuts Yahoo Finance · 30d ago
- Flutter upgraded, AppFolio downgraded: Wall Street's top analyst calls Yahoo Finance · 7 Oct 2026
- Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You Trade Yahoo Finance · 6 Oct 2026
- Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note Yahoo Finance · 1 Oct 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
ICCCImmuCell Corporation
ENTXEntera Bio Ltd
VRCAVerrica Pharmaceuticals Inc
RANIRani Therapeutics Holdings Inc
ONCYOncolytics Biotech Inc
BDTXBlack Diamond Therapeutics Inc
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-19 | SEBELIUS KATHLEEN G | Director | 56,818 | $50,000 | |
| 2026-05-18 | PARIKH SHAMIK J | Officer | 45,887 | $41,147 | |
| 2026-05-18 | SANDER DALE A | Chief Financial Officer | 45,887 | $41,147 | |
| 2026-05-18 | CONSTANTINO MICHAEL T | Director | 11,000 | $9,840 | |
| 2025-11-14 | SANDER DALE A | Chief Financial Officer | 311,100 | · | |
| 2025-11-14 | PARIKH SHAMIK J | Officer | 311,100 | · | |
| 2025-08-20 | NIKLASON LAURA E | Chief Executive Officer | 2,241,045 | $3,733,191 | |
| 2025-08-20 | DOUGAN BRADY W | Director | 2,241,045 | $3,733,191 | |
| 2025-04-14 | SCHEESSELE WILLIAM JOHN | Officer | 6,493 | $9,999 | |
| 2025-04-10 | SANDER DALE A | Chief Financial Officer | 20,000 | $30,600 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-04-13 | Ro Khanna | Democrat | Purchase | 1K–15K |
| 2024-05-03 | Tommy Tuberville | Republican | sell | 1K–15K |
| 2024-05-03 | Tommy Tuberville | Republican | sell | 15K–50K |
| 2024-03-21 | Tommy Tuberville | Republican | buy | 1K–15K |
| 2024-03-21 | Tommy Tuberville | Republican | buy | 1K–15K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $1.00 | +31.8% | · | $1,318 | +31.8% |
| 2 months | $0.64 | +104.3% | · | $2,043 | +104.3% |
| 3 months | $1.14 | +15.6% | · | $1,156 | +15.6% |
| 6 months | $1.31 | +0.6% | · | $1,006 | +0.6% |
| 1 year | $2.67 | -50.6% | · | $494 | -50.6% |
| 2 years | $7.20 | -81.7% | · | $183 | -81.7% |
| 3 years | $4.29 | -69.3% | · | $307 | -69.3% |
| 5 years | $11.10 | -88.1% | · | $119 | -88.1% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever HUMA does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.